Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
about
Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreasMedical management of brain tumors and the sequelae of treatment.Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsAdvances in small bowel neuroendocrine neoplasiaNew therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.Biologics in gastrointestinal and pancreatic neuroendocrine tumorsOutcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETsExpression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasmA prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agentsHealth-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapyThe Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.Update on management of midgut neuroendocrine tumors.A phase II study of axitinib in advanced neuroendocrine tumors.Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumoursEmerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians.Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs).The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancerClinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors.Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problemsSunitinib malate for the treatment of pancreas malignancies--where does it fit?Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy.Management of advanced and/or metastatic carcinoid tumors: historical perspectives and emerging therapies.Evolving treatment strategies for management of carcinoid tumors.The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy.Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.Pancreatic NETs: where do we stand now?Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients.Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.
P2860
Q26752757-126DED24-8609-4EED-B09B-925B0FE09855Q26992174-BE96D0DA-C703-4B6F-904B-EDD7B1BC9B2CQ26996521-8D524E53-2DD7-4282-B89F-4D7C4B5C5941Q27000397-2C71633C-91E5-451C-9D1C-6E4B4D57C2DBQ30364864-ACCC3CFC-D0FD-44EA-BA51-5040EE5CA3B5Q30412393-E98A46F1-AFD7-46CC-94AD-3AAA09C693DCQ31170918-8214F160-7362-4B4B-B48E-C8EA78858753Q33405625-A5861A66-DAC2-43F6-9075-1E995B5444C2Q33895557-BA777F53-F67B-46D7-B2A0-5456716ABBACQ33948026-61EFFBD5-881F-450E-AFF8-3D46BC6D264EQ34029197-223B41D3-03B5-4D07-A5A9-33FC9E7CDC85Q35020652-6E95D5CC-F598-4D4A-841E-F0D6A9A82882Q35081993-3AF87127-CBCA-41D6-B5AB-FC773DECA64BQ35128224-C79CAF31-225B-4BE2-BF9C-7089EAF848DDQ35677887-4D4EBE6A-3082-47EC-8C16-9FB0910102BFQ35738251-D36FA0AE-8273-49A0-A196-AC9C2564A643Q36708349-87AAD639-67D9-4E5E-9226-38A8CD659F3AQ36821570-9C497A40-CAB9-49C5-8D0B-975DC1E61FF4Q37017037-4F7CDEA7-97E6-41ED-8DA5-A6FE64D18162Q37025143-7A38ECAB-63A7-4033-99DE-6F255FD80268Q37131421-9DB1C62C-DB2F-4DD2-98D8-208F49FB9A09Q37182210-FCF652D4-0279-44D9-BD31-FCC064FD4362Q37255846-4BA8F60A-F732-451E-93B7-342CAC690B4BQ37362261-84B20A35-A96B-472C-B576-2DD69C0F89E2Q37372483-F4A6FAFB-F3EE-4E47-B3EB-77F1AFDE4A40Q37594074-17705B15-D99E-4779-A4CC-B230164B53B7Q37624511-7443DBBF-0BCC-4112-BC0E-9BE84802E1A2Q38066186-5CD7F06D-B6B9-41C4-B8C4-0DBA1500AC2EQ38067034-E12D0933-6209-4268-95FD-4F1BF28233D8Q38076275-B2358D87-6B53-406C-8418-43BFD144C1E2Q38086310-6A17A02F-F5C3-484E-8D93-23CE2BC90DA8Q38096476-650E1B4A-5334-4566-AA0B-804F179C7197Q38112804-72F2BD57-13AE-432D-BDBB-48637F463FA1Q38124702-6D93487B-B042-47D0-8678-2B487781D621Q38168953-21719880-88A5-4F7C-AC17-FA9AB4BF0DD8Q38174516-98E1353D-6CF0-4D14-BED2-C77C8BE23739Q38181004-3FD764AB-0F22-4080-81CD-DFA539D95A7CQ38225877-979EB6B9-414D-4827-AEA7-71E2827B1D84Q38250467-F8FD35E6-004A-4045-BAB4-AE2799FDE1ACQ38331666-78E36814-9C51-492E-B73F-9531315A069B
P2860
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Prospective study of bevacizum ...... dvanced neuroendocrine tumors.
@ast
Prospective study of bevacizum ...... dvanced neuroendocrine tumors.
@en
type
label
Prospective study of bevacizum ...... dvanced neuroendocrine tumors.
@ast
Prospective study of bevacizum ...... dvanced neuroendocrine tumors.
@en
prefLabel
Prospective study of bevacizum ...... dvanced neuroendocrine tumors.
@ast
Prospective study of bevacizum ...... dvanced neuroendocrine tumors.
@en
P2093
P2860
P50
P356
P1476
Prospective study of bevacizum ...... dvanced neuroendocrine tumors.
@en
P2093
Craig C Earle
Jeffrey W Clark
Jennifer A Chan
Keith Stuart
Lawrence Blaszkowsky
Matthew H Kulke
Pankaj Bhargava
Peter C Enzinger
P2860
P304
P356
10.1200/JCO.2011.40.3147
P407
P577
2012-07-09T00:00:00Z